• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Defence and Security Market
    Defence and Security News
    Defence and Security Stocks
    • Defence and Security Market
    • Defence and Security News
    • Defence and Security Stocks
    security investing

    BIO-key Previews 2017 Results Including Revenue Increasing 110 Percent to $6.3 Million

    Jocelyn Aspa
    Feb. 20, 2018 09:26AM PST
    Defence and Security Investing

    BIO-Key International (NASDAQ:BKYI) has announced unaudited preliminary results for its Q4 ended December 31, 2017 and a recap of its 2017 operating achievements. As quoted in the press release: BIO-key expects to report audited results for its FY 2017 in late March, details on the exact date and time of the earnings call will be …

    BIO-Key International (NASDAQ:BKYI) has announced unaudited preliminary results for its Q4 ended December 31, 2017 and a recap of its 2017 operating achievements.

    As quoted in the press release:

    BIO-key expects to report audited results for its FY 2017 in late March, details on the exact date and time of the earnings call will be announced in coming weeks.

    BIO-key provided the following unaudited preview of its Q4 and full year 2017 results.

    Q4’17Q4’16Chg.20172016Chg.
    Revenue$3.0M$1.7M+76%$6.3M$3.0M+110%
    Gross Profit$2.2M$1.4M+57%$3.0M $2.2M+36%
    Net Income (Loss)$0.5M($0.5M)+200%($4.2M)($4.2M)–

    BIO-key’s CEO Michael DePasquale commented, “In the past year, we worked to lay the foundation for long-term revenue growth. We focused on increasing our base of customers, growing our distribution channels, and launching a new line of products to deliver BIO-key’s secure biometric technology to both enterprise and consumer customers. Our efforts resulted in solid results including net income in our fourth quarter and 110% revenue growth in 2017. We are pleased with BIO-key’s performance as it reflects the ramping demand and growing adoption of our secure biometric solutions.  I am confident that we are on the right track as we pursue our goal of becoming a profitable company.”

    Click here to read the full press release.

    security investing
    The Conversation (0)

    Go Deeper

    AI Powered
    BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

    BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

    NASDAQ:BKYI

    Bio-Key Maintains Guidance Amid Low Cashflow

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Defence and Security Investing Stocks

    Aether Global Innovations

    AETH:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×